CD73-IN-1 is primarily used in research settings to study the role of CD73 in various biological processes. It acts as an inhibitor of CD73, an enzyme involved in the production of adenosine, which plays a significant role in immune regulation and tumor progression. Researchers utilize CD73-IN-1 to investigate its potential in modulating immune responses, particularly in cancer immunotherapy. By blocking CD73 activity, it helps in understanding how adenosine signaling affects tumor microenvironment and immune cell function. This compound is also explored for its potential therapeutic applications in autoimmune diseases and chronic inflammatory conditions, where adenosine signaling is implicated. Its use in preclinical studies aids in the development of new strategies to enhance anti-tumor immunity and improve treatment outcomes.